AMHR2 Vaccine Composition for Ovarian Cancer Recurrence Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for ovarian cancer, such as those using whole tumor homogenate or specific tumor-associated antigens, have provided only modest results, leading to high recurrence rates and low five-year survival rates, necessitating new compositions and methods for treatment and prevention.
Innovation Solution
Induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2) through administration of AMHR2 polypeptides, antigen-presenting cells, and AMHR2-primed lymphocytes, potentially combined with adjuvants and anti-cancer agents, to target ovarian cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic approaches using whole tumor homogenate or tumor-associated antigens are used, then treatment can be administered, but the immune response is insufficient leading to high recurrence rates and low survival rates
Solution Approach 1:
The patent uses composite vaccine formulations combining multiple antigen types (AMHR2 polypeptide, nucleic acid encoding AMHR2, antigen-presenting cells, and primed lymphocytes) to create a synergistic immune response that overcomes the insufficiency of single-antigen approaches and achieves reliable treatment efficacy
Solution Approach 2:
The patent modifies immune response parameters by using adjuvants and multiple antigen delivery formats to enhance the strength and durability of the immune response, transforming the weak response from conventional therapies into a robust protective response against ovarian cancer
2Productivity
If strong immune responses are induced against ovarian cancer antigens, then tumor growth is inhibited, but autoimmune complications may occur
Solution Approach 1:
The patent targets the immune response locally to ovarian cancer tissue by using antigen-presenting cells and primed lymphocytes that specifically recognize AMHR2 on tumor cells, concentrating the immune attack at the tumor site while sparing normal tissues and minimizing autoimmune complications
Solution Approach 2:
The patent uses antigen-presenting cells as intermediaries that process and present AMHR2 antigens in a controlled manner, mediating between the vaccine antigen and the immune system to generate a targeted response that inhibits tumor growth without causing widespread autoimmune reactions
3Duration of action of stationary object
If therapeutic vaccines are administered, then immune response is induced, but the response must be sustained over time to prevent recurrence
Solution Approach 1:
The patent employs primed lymphocytes and antigen-presenting cells that are pre-prepared and loaded with tumor antigens before administration, creating an immediate and sustained immune response that provides long-term protection against cancer recurrence without requiring extended treatment periods
Solution Approach 2:
The patent creates continuous immune surveillance by using antigen-presenting cells and primed lymphocytes that maintain persistent antigen presentation and T-cell activation, ensuring continuous protective immunity against ovarian cancer recurrence over an extended period
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach induces a robust immune response, including type 1 and type 17 immune responses, effectively inhibiting ovarian cancer growth and recurrence with minimal autoimmune complications and no impact on fertility, as demonstrated in mouse models.
Implementation Method 1
administration of AMHR2 polypeptides, antigen-presenting cells, and AMHR2-primed lymphocytes, potentially combined with adjuvants and anti-cancer agents, to target ovarian cancer
Data Source
AI summary
Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2).